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Immune checkpoint inhibitors are a new form of immunotherapy that has 
transformed the treatment landscape for an ever-increasing number of malignancies. 
While these medications utilize and enhance the immune system to treat malignancies, 
they can also have significant side effects, termed immune related adverse events, that in 
many ways resemble autoimmune disease states. One such example is inflammatory 
arthritis, which has been found to resemble a number of different presentations, including 
rheumatoid arthritis and seronegative spondyloarthropathies. In addition to these 
traditional inflammatory arthritis phenotypes, worsening of pre-existing arthritis is 
another subgroup of inflammatory arthritis that has previously not been considered in this 
population. Furthermore, while the effects of these autoimmune arthropathies on 
functionality is well-documented, it is not known whether there is a significant effect on 
functionality in patients that experience immune checkpoint inhibitor-induced arthritis. 
Given that patient reported outcomes are a validated and routinely utilized measure of 
functionality and quality of life, the Health Assessment Questionnaire, pain visual 
analogue scale and Patient Global Assessment were used to measure these outcomes 
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following diagnosis. Our aim here is to explore the subtypes of inflammatory arthritis that 
result from this type of treatment and its overall effect on functionality and quality of life.  
 
Methods:  
This study was a retrospective review of patients at one academic center who 
experienced an inflammatory arthritis resulting from immune checkpoint inhibition and 
required a referral to a rheumatologist for further work-up. Patients were evaluated in 
clinic at which time they also completed a Health Assessment Questionnaire as part of 
standard of care. Once patients were evaluated, their inflammatory arthritis was classified 
based on which clinical arthritis that it matched most closely, including polymyalgia 
rheumatica, rheumatoid arthritis, seronegative spondyloarthritis, or an exacerbation or 
osteoarthritis. Other demographic information such as gender, age, and race were also 
collected. Patient questionnaires were scored and compared to the type of inflammatory 
arthritis to assess for any correlations.  
 
Results:  
We found 30 patients that had an inflammatory arthritis resulting from immune 
checkpoint inhibition, with 12 having a polyarthritis similar to rheumatoid arthritis, 11 
patients having osteoarthritis exacerbation, 4 patients with a polymyalgia rheumatica 
arthritis phenotype and 3 patients with a spondyloarthopathy. In terms of the patient 
reported outcomes, the overall score was 0.57 ± 0.47, indicating that there was little 
effect of these arthropathies on overall functionality. The pain visual analogue scale had 
vi 
 
an average score of 41.8 ± 31.4 mm and the Patient Global Assessment had an overall 
score of 25.6 ± 26.7 mm.  
 
Discussion:  
The overall results suggest that the inflammatory arthritis phenotypes do not 
significantly impact the functionality or quality of life of most patients who experience 
this side effect. Given that the use of immune checkpoint inhibitors will continue to grow, 
the overall need to better understand the resulting arthritis presentations is key. This is 
perhaps most true for those with pre-existing osteoarthritis, given the widespread nature 
of the disease in the general population and the prominence of the exacerbation as seen in 
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Background on Immune Checkpoint Inhibitors: 
Cancer immunotherapy in the form of immune checkpoint inhibitors has 
revolutionized the treatment of many types of cancers and allowed for significant 
improvement in outcomes, even in those with advanced disease (1). These 
immunomodulatory drugs are composed of monoclonal antibodies that provide a crucial 
link in allowing the immune system to carry out its natural function in destroying cancer 
cells. Currently, anti-cytotoxic T-lymphocyte-associated antigen 4 drugs in addition to 
anti-programmed cell death-1 and anti-programmed cell death ligand-1 drugs, are the two 
classes of immune checkpoint inhibitors that have been approved for use in the clinical 
setting and about which the most information is known regarding their therapeutic profile 
(2, 3).  Table 1 provides a summary of immune checkpoint inhibitors that are currently 
FDA approved and the indications for which they have received approval. Notably, there 
are already a significant number of indications for which these medications have received 
approval, and the number continues to grow. With the already varied and ever increasing 
number of malignancies for which immune checkpoint inhibitors are used, exploration of 
their mechanisms and clinical profile will provide significant and relevant information on 





Table 1. Approved Immune Checkpoint Inhibitors with Approved Indications. The 
table demonstrates that there are several immune checkpoint inhibitors that are approved 
for use, and have a wide array of approved indications. (4-10) 
 
Drug: Subclass: Year of 
FDA 
Approval: 
Indications (includes indications for which 
approval is given as part of a combination 
therapy)  
Ipilimumab CTLA-4 2011  Metastatic melanoma 
 Renal Cell Carcinoma 
Nivolumab PD-1 2014  Metastatic Melanoma 
 Metastatic Non-Small Cell Lung Cancer 
 Renal Cell Carcinoma 
 Metastatic Small Cell Lung Cancer 
 Hodgkin Lymphoma 
 Recurrent of Metastatic Squamous Cell 
Carcinoma 
 Hepatocellular Carcinoma 
 Microsatellite Instability- High or 
Mismatch Repair Deficient Metastatic 
Colorectal Cancer 
Pembrolizumab PD-1 2014  Metastatic Melanoma 
 Non-Small Cell Lung Cancer 
 Small Cell Lung Cancer 
 Head and Neck Squamous Cell 
Carcinoma 
 Classical Hodgkin Lymphoma 
 Primary Mediastinal Large B-cell 
Lymphoma 
 Urothelial Carcinoma 
 Microsatellite Instability-High Cancer 
 Gastric Cancer 
 Esophageal Cancer 
 Cervical Cancer 
 Hepatocellular Carcinoma 
 Merkel Cell Carcinoma 
 Renal Cell Carcinoma 
 Endometrial Carcinoma 
Cemiplimab PD-1 2018  Metastatic Cutaneous Squamous Cell 
Carcinoma 
Atezolizumab PD-L1 2016  Urothelial Carcinoma 
 Non-Small Cell Lung Cancer 
 Triple Negative Breast Cancer 
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 Small Cell Lung Cancer 
Avelumab PD-L1 2017  Metastatic Urothelial Carcinoma 
 Metastatic Merkel Cell Carcinoma 
 Renal Cell Carcinoma 
Durvalumab PD-L1 2017  Metastatic Urothelial Carcinoma 
 Non-Small Cell Lung Cancer 
 
Although the exact mechanism of action is still unknown, the current model 
suggests that the anti-CTLA-4 mechanism works by inhibiting an inhibitory signal; 
specifically, inhibiting the normal interaction between antigen presenting cells and T-
cells that would otherwise inhibit T-cell activation (11). During the normal immune 
response, T-cells interact with antigen presenting cells in two different ways. First, the T-
cell receptor on the T-cell interacts with the antigen bound to MHC molecules on the 
antigen presenting cells and the CD80 or CD86 proteins on the antigen presenting cell 
interacting with the co-stimulatory receptor, CD28, on the T-cell (11, 12). The CD28-
CD80/86 interaction works as a co-stimulatory interaction that allows for activation of 
the T-cell. However, in addition to CD28, CTLA-4 on the T-cell can also bind to 
CD80/86, but with higher affinity than can CD28. The result is that when this CTLA-4-
CD28 interaction occurs, the T-cell response is inhibited. In tumor cells, CTLA-4 can be 
upregulated, causing increased binding between the CD80/86 and CTLA-4, thereby 
downregulating T-cell activation with cancer cells ultimately becoming tolerant to the 
normal immune response and allowing them to proliferate (11, 12). Anti-CTLA-4 drugs, 
such as ipilimumab, block this CTLA-4 and CD80/86 interaction via binding of the drug 
antibodies to CTLA-4, thereby preventing the inhibitory interaction, leading to a more 
robust immune response (13).  
 
4 
Similar to the CTLA-4 mechanism, PD-1 is a receptor on T-cells that, when 
binding to its ligand PD-L1, functions to downregulate the T-cell response. During the 
normal immune response, PD-L1 becomes upregulated as a result of inflammatory 
cytokines. This upregulation serves to protect surrounding tissues and acts to limit the 
overall response. In tumor cells, PD-L1 is upregulated likely as an endogenous adaptation 
to the normal immune response, thereby preventing T-cell activation within the tumor 
microenvironment (14). Therefore, by blocking the PD-1-PD-L1 interaction, T-cell 
activation can occur, causing anti-tumor immune activity. Currently, there are several 
FDA-approved drugs that work by this mechanism, with pembrolizumab being one 
example of a PD-1 inhibitor, and atezolizumab being one example of a PD-L1 inhibitor.  
 
Side Effects of Immune Checkpoint Inhibition: Immune Related Adverse Events 
While immune checkpoint blockade provides a boosted immune response to a 
number of various cancers, these immunotherapies have also been associated with 
inflammatory side effects, termed immune related adverse events (15). The most 
commonly affected organ systems are the skin, gastrointestinal tract, endocrine systems 
and liver, but any organ system can be affected (15,16). Table 2 provides an overview of 
some of these immune related adverse events. While by no means an exhaustive list, 
Table 2 does provide an idea of the expansiveness of the potential side effects that can be 
observed with use of these medications. Besides the varying types of adverse events, the 
frequency of these adverse events also varies by medication, with some events, such as 
colitis, observed more often in those treated with CTLA-4 agents and others, such as 
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pneumonitis, seen more commonly in those treated with anti-PD-1 agents (16). Not only 
has frequency of these events been observed to vary by medication, severity also varies. 
CTLA-4 drugs generally have more severe side effects than the PD-1/PD-L1 drugs, with 
combination therapy, consisting of CTLA-4 and either PD-1 or PD-L1 medications used 
together in tandem, having more severe side effects than either drug used along as 
monotherapy (16). Indeed, there has been extensive research on these immune related 
adverse events as more severe presentations can necessitate treatment discontinuation 
which can ultimately affect cancer progression and survival (17,18). More commonly, 
these immune complications result in less severe side effects that may require temporary 
immunosuppression, which itself can lead to host of issues, not least of which is the 
potential for interfering with the mechanism of the immune checkpoint inhibitors 
themselves by suppressing the immune system (16-18). Additionally, given how recent 
approval and use of these medications in the clinical setting has been, long term side 
effects are unclear. It is possible that these immune related adverse events may continue 
well after treatment with immune checkpoint inhibitors has stopped, or may have a 
delayed onset that has not yet been observed. There is data suggesting that the anti-cancer 
effect lasts for up to 5 years after the initiation of ICIs. The knowledge in this field is 
rapidly changing as more and more indications are currently added in regards to different 
types of cancers. The long-term effects of immune checkpoint inhibitors are currently 
being investigated and treatment for these events continues to evolve. While initial efforts 
were to treat the irAEs early with high doses of steroids, more recent data suggests that 





Table 2: Immune Related Adverse Events by Organ System. The adverse events 
listed here provide an indication of some of the adverse events that have been reported 
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-Type 1 diabetes mellitus 













-Guillain Barre syndrome 















Overview of Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis 
In looking at other systems that are affected by the immune checkpoint inhibitors, 
the musculoskeletal system is another area where inflammatory side effects have been 
reported in the form of inflammatory arthritis (20, 21). While these potential side effects 
are known, information about these specific manifestations remains less well 
characterized (21). Based on reviews of clinical data and data obtained from clinical 
trials, current data reveal the incidence of immune checkpoint inhibitor induced 
inflammatory arthritis to be between 1% and 7% (22-24) while the incidence of 
arthralgia, or nonspecific joint pain, is estimated to be anywhere between 1% and 43% 
(21). There is also data suggesting the irAEs affecting the musculoskeletal system cause 
the most quality of life impairment of all the irAEs. These figures also vary in relation to 
each of the different drugs and their different combination therapies based on data 
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correlated across multiple clinical trial data and other clinical reports (23). For example, 
ipilimumab is reported to have an arthralgia rate of 5% while rates with pembrolizumab 
have been reported as high as 12% (21). While these figures do represent advancement in 
our understanding of prevalence of inflammatory arthritis in this setting, it is clear that 
further study is needed.  
 
In addition to the variance in the incidence of the arthralgia and inflammatory 
arthritis, there is also limited information regarding the clinical presentation of these 
symptoms. Currently, most of the data for this population is based on limited case reports 
and small case series. The largest previously reported cohort of immune checkpoint 
inhibitor-induced inflammatory arthritis patients consists of thirty patients and provides a 
description of the affected joints at arthritis onset and type of joint involvement based on 
the type of treatment received, being either PD-1 or PD-L1 monotherapy or combination 
PD-1/PD-L1 and CTLA-4 therapy, given that no CTLA-4 monotherapy patients were 
found in their review. Specifically, it was reported that those that received combination 
therapy experienced initial symptom onset with knee monoarthritis followed by 
involvement of the small joints of the hands and feet. Another arthritis phenotype 
consistent with a reactive arthritis was also seen in patients who received combination 
therapy and experienced other immune related adverse events concurrently, but not in 
those that received only monotherapy. Meanwhile, for those that received monotherapy, 
onset was observed in the small joints (25). The small joint involvement was described as 
similar to rheumatoid arthritis, an autoimmune inflammatory arthritis, while the large 
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asymmetric knee arthritis followed by the small joint arthritis was a less specific profile 
most consistent with an oligoarthritis, or an inflammatory arthritis affecting only a small 
number of joints, without significant resemblance to a more distinctive inflammatory 
arthropathy (25). Other case reports also suggest that development of rheumatoid arthritis 
and rheumatoid arthritis-like symptoms has occurred in this patient population (26). 
 
Clinical Presentations of Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis 
A more comprehensive look at rheumatoid arthritis reveals an inflammatory 
arthritis that is defined in large part by swelling of the joints as seen on physical exam. 
The typical clinical presentation of patients with rheumatoid arthritis is joint swelling, 
with polyarticular involvement in the small joints of the hands and feet, namely the PIPs, 
MCPs, wrists and MTPs, being a finding more indicative of this arthritis phenotype than 
large joint involvement (27). This clinical finding is also reflected in the American 
College of Rheumatology criteria for the diagnosis of rheumatoid arthritis. In particular, 
more points are awarded to patients who have small joint involvement over large joint 
involvement (28). Figure 1 shows the overall point system that define the diagnostic 
criteria, which reflects this reliance on small joints. In order to receive a diagnosis of 
rheumatoid arthritis, patients must meet any criteria below with a minimum of 6 points 
required for diagnosis (28). Therefore, we see that small joints symptoms alone can 
award 3 points, half of those required to obtain diagnosis. Furthermore, another 
significant part of the overall diagnostic criteria are serologies. A look at Figure 1 
indicates that up to 3 points can be awarded for highly positive serologies, with presence 
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of any serology garnering 2 points. Therefore, if a patient were to have 4 swollen small 
joints and highly positive serologies, that alone is enough for a diagnosis. However, 
despite the importance in the serologies in the diagnosis of rheumatoid arthritis, patients 
with inflammatory arthritis resulting from exposure to immune checkpoint inhibitors 
generally do not have negative serologies, or at least have negative rheumatoid factor and 
anti-citrullinated peptide antibodies, the two serologies associated with rheumatoid 
arthritis (29-31). Although some cohorts have shown seropositivity in those patients who 
have developed a picture similar to rheumatoid arthritis after exposure to these therapies, 
it is still poorly understood whether or not the seropositivity is a result of exposure or if 
patients were seropositive prior to exposure (32). Detection following exposure is 
therefore of limited value and makes it unclear whether patients are developing true 
rheumatoid arthritis or a phenotypically similar clinical entity. Despite this, the 






Figure 1. Rheumatoid Arthritis Classification Criteria. The point system here 
provides a summary of the criteria used to diagnose rheumatoid arthritis, which can be a 
useful tool for assessing patients with an irAE of inflammatory arthritis (28). 
 
 
Aside from the rheumatoid arthritis-like presentations, symptoms that resemble 
polymyalgia rheumatic have been described as another manifestation in those treated 
with immune checkpoint inhibitors (25-27). Polymyalgia rheumatica, or PMR, is an 
inflammatory condition of unknown etiology that can cause girdle pain around the 
shoulders and hips and is often associated with elevated inflammatory markers, especially 
elevated sedimentation rates, as well as good response to treatment with corticosteroids. 
(33-36). The girdle pain has been demonstrated to be a result of inflammation of the 
periarticular tissues, including the bursae and tendons of the hips and shoulders, that 
leads to the characteristic pattern of stiffness and aching. From an immunologic 
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perspective, CD4+ cells in the form of Th17 cells as well as IL-6, both of which have 
pro-inflammatory properties, have been measured at higher levels in the blood in affected 
individuals. Although no data is present on immune checkpoint inhibitor induced PMR 
outside of case reports or as case series, these reports do show that this type of an 
inflammatory arthritis does occur following treatment with immune checkpoint 
inhibition. Much like for rheumatoid arthritis, there is a current model for PMR that 
provides guidelines on the typical presentation that can be used for classification 
purposes, though notably not for diagnostic purposes, as is the case with rheumatoid 
arthritis. In general, these patients are found to be over the age of 50, have new onset 
bilateral shoulder pain in the absence of another etiology, elevated C-reactive protein 
and/or sedimentation rate, morning stiffness for greater than 45 minutes, as well as new 
onset pain in the hips (37). In addition, absence of any peripheral swelling or synovitis on 
physical exam alongside negative serologies, including rheumatoid factor and anti-
citrullinated peptide antibodies, also points more towards PMR as opposed to another 
form of inflammatory arthritis (37). Using these criteria, PMR has therefore been used as 
a model to classify patients who experience these constellation of symptoms following 
treatment with immune checkpoint inhibition. 
 
Much like the polymyalgia rheumatic phenotype, seronegative 
spondyloarthropathies have also been reported as part of the spectrum of inflammatory 
arthritis phenotypes that have been observed following immune checkpoint inhibitor 
therapy. In general, this type of arthritis is so classified because it affects the vertebral 
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column (38). Clinically, this type of arthritis is observed with low back pain, which may 
indicate sacroiliitis, asymmetrical peripheral oligoarthritis, and inflammatory 
enthesopathy, which describes inflammation at the site of attachment of bone to a 
ligament or muscle (39). Interestingly, this type of arthritis can also have significant 
extra-articular manifestations, such as psoriasis in psoriatic arthritis and uveitis or iritis in 
a reactive arthritis, to name a few (38, 39). On a more basic level, there is a strong link 
between the HLA-B27 genetic variant and development of seronegative 
spondyloarthropathies, in particular ankylosing spondylitis. (40) Additionally, patients 
are usually negative for the rheumatoid factor serology, hence the designation of 
seronegative, there are a number of pro-inflammatory cytokines that have been 
implicated in the pathogenesis of these diseases, including TNF-alpha, IL-23, and IL-17 
(40, 41). In looking at pre-existent reports on seronegative spondyloarthropathies, 
psoriatic arthritis has been noted to have occurred in two separately published cases while 
reactive arthritis has been reported more commonly (42-44). Even in rare cases, 
ankylosing spondylitis has been reported to develop after treatment with immune 
checkpoint inhibitors (45). It is therefore clear that seronegative spondyloarthropathies 
are a form of inflammatory arthritis that can develop following treatment with immune 
checkpoint inhibitors.  
 
Immune checkpoint therapy can cause inflammatory arthritis of various 
phenotypes, as has been described in previous literature. However, one form of arthritis 
that may also be related to the development of arthritis and arthralgias in these patients is 
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osteoarthritis. Osteoarthritis is often mischaracterized solely as a degenerative joint 
disease that is related to age and mechanical use. While these are factors that play a role 
in this disease, it is not the case that it is solely related to these factors (46-48). In fact, it 
has been shown that inflammation plays a significant role in the development and 
progression of osteoarthritis (48). Within the joint space itself, the chondrocytes that 
produce the cartilage are, for the most part, dormant and show little activity (49). 
However, these cells can become activated for a number of reasons, generally related to 
environmental disturbances, including mechanical stress, oxidative stress, or 
inflammatory infiltrate in surrounding tissues, to name a few (50). Once the joint 
undergoes this process of activation, inflammation can play a significant role in disease 
progression (48, 50). Chemokine and cytokine receptors on the chondrocytes lead to 
continued activation of these cells, which can then lead to the formation of degradation 
products from the higher cellular turnover. As more degradation products are produced, 
the cartilage matrix of the joint begins to degrade significantly, leading to production of 
further degradation products, which themselves can then activate other chondrocytes, in a 
feedback loop of inflammation and ultimately disease progression (48, 50). Synovitis is 
also present in the joints of those with osteoarthritis, though to a varying degree and to a 
much less severe degree than what is seen in rheumatoid arthritis (50). Despite this, 
synovitis can still lead to remodeling of the joint space and overall progression of 
osteoarthritis in much the same fashion as rheumatoid arthritis (50). In terms of clinical 
presentation for osteoarthritis, most patients present with complaints of pain in the joint 
that may be intermittent as well as with varying degrees of severity. The pain is often 
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worsened with physical activity and improved with rest, but can be present in the absence 
of any initiating physical movement. In more progressed stages, joint deformity is also 
another indicator of osteoarthritis. Deformity is often noted in the smaller joints of the 
hands and feet, but this can also occur in larger joints such as the knees. Other clinical 
factors include reduced function, swelling, and stiffness. Although no diagnostic criteria 
are used for osteoarthritis, patients that meet the constellation of symptoms are generally 
classified as such. 
 
In looking at the role that immune checkpoint inhibitors may play in 
osteoarthritis, no clinical data has yet been reported. It is possible that patients experience 
osteoarthritis exacerbation as a result of their treatment with these medications, but given 
the less apparent clinical presentation of inflammation in osteoarthritis as well as the 
general mischaracterization of osteoarthritis as a purely mechanical joint disease, it may 
be significantly under-diagnosed. Indeed, mouse models of PD-L1 blockade have shown 
that osteoarthritis is worsened, with more cartilage damage and increased levels of pro-
inflammatory cytokines observed (51). PD-L1 was also more highly expressed in these 
mice than would normally be expected, indicating that administration of PD-1 or PD-L1 
inhibitors leads to the outcomes observed (51). 
 
Patient Reported Outcomes in Inflammatory Arthritis 
While there are descriptions of inflammatory arthritis and arthralgias in the 
literature, current investigations remain focused on providing descriptive information 
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about the presentation of symptoms after treatment initiation with immune checkpoint 
inhibitors (24-26, 52). However, there has been little focus on patient reported outcomes 
and quality of life measures for these medications. Patient reported outcomes have more 
recently been recognized as an important part of improving patient care by measuring 
functional capacities and quality of life which leads to longer survival, improved quality 
of life and more effective symptom management (53, 54). This includes the field of 
oncology, where patient reported outcomes are important aspects of current practice. 
These patients reported outcomes have helped to facilitate conversations between the 
clinician and patient about symptoms from underlying disease and treatment side effects 
and lead to overall improved outcomes (54).  Such information has proven valuable in 
determining the extent to which patients experience symptoms associated with their 
cancer and its treatment and has been shown to enhance the treatment they subsequently 
receive for these symptoms (55-57). 
 
Patient reported outcomes have also been utilized in patients with chronic 
conditions such as rheumatoid arthritis (58). Much like the oncology setting, the 
utilization of patient reported outcome measures in this setting is designed to capture 
information from patients about their health-related quality of life (58). For rheumatoid 
arthritis in particular, the Health Assessment Questionnaire has long been used to study 
functionality outcomes (59). This assessment is used to determine functionality changes 
in this patient population by asking a series of twenty questions separated into eight 
domains that are related to activities of daily living including dressing, grooming, arising, 
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eating, walking, hygiene, reach, and grip that captures information regarding the function 
of both upper and lower extremities. Patients are asked to rate their ability to perform 
these tasks on a scale of 0, which indicates that the patient is able to complete the task 
without difficulty, and 3, which indicates that the patient is unable to complete the task 
(59). Based on the scores from these eight domains, a final overall score, which is again 
based on the 0 to 3 scale previously described, indicates an overall level of disability in 
relation to their arthritis symptoms. The degree to which these questions accurately 
represent patient symptoms and is sensitive to change has been well studied and validated 
both in the clinical setting and through clinical trials (59). Alongside its use in 
rheumatoid arthritis, the Health Assessment Questionnaire has also been utilized in 
osteoarthritis as well as other rheumatic conditions. Osteoarthritis has significant impact 
on the overall functionality of affected patients, given that it can have a widespread 
distribution throughout the musculoskeletal system and leads to progressive deterioration 
with few effective treatment options (60, 61). As such, the utility of this patient reported 
outcome has been validated in clinical use for this population (62). In looking at other 
disease states, the Health Assessment Questionnaire has also been shown to be of use in 
assessing disability, with part of the original purpose for this outcome measure being that 
of determining functionality and disability across a number of different disease states. 
 
Moreover, while the Health Assessment Questionnaire has become an important 
outcome measure of functional status in patients with rheumatoid arthritis, functional 
status has itself been linked to a number of predictive factors such as mortality, 
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healthcare utilization and work disability in this population, each of which has significant 
effects on patient outcomes and quality of life (63-70). It can also act as a substituted 
measure of the success or failure of treatment. Improvement of the score of the Health 
Assessment Questionnaire can even be used as a surrogate for improving physical 
function without any other objective measures (71). The utility of this patient reported 
outcome is therefore multifaceted in the information it can provide and a useful tool in 
the clinical setting. 
 
In addition to the use of the Health Assessment Questionnaire, visual analogue 
scales are also important measures for patients with rheumatic conditions, including those 
with a diagnosis of inflammatory arthritis (72-75). One particular type of visual analogue 
scale is the pain visual analogue scale, which acts as a reasonable measure of pain and the 
functionality in terms of the activities of daily living. It is a simple measure to administer 
and valuable information can be obtained about how pain is affecting their functionality 
and level of disability. Its utility in inflammatory arthritis has been shown most 
prominently in rheumatoid arthritis, where it has been demonstrated to provide this 
information (75-77). Perhaps unsurprisingly, the pain scale has also shown statistically 
significant positive correlation with the overall score from the Health Assessment 
Questionnaire, which indicates the effect that pain has on this particular patient reported 
outcome measure. While no data exists on the use of this measure in inflammatory 
arthritis resulting from use of immune checkpoint inhibitors, it is clear from autoimmune 
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inflammatory arthritic phenotypes that this measure can provide useful information both 
about pain levels and the correlation of this pain to overall functionality and disability.   
 
Similarly, another patient reported outcome that has been utilized in rheumatic 
diseases, including inflammatory arthritis, is the Patient Global Assessment (78). Like the 
pain scale described previously, the Patient Global Assessment as patients to rate how 
they feel about their disease in the form of a visual analogue scale that represents a 
continuous set of ratings in which patients can mark based on their own impression of 
their disease. However, in contrast to the pain scale, this measure seeks an overall picture 
of disease, including consideration about physical, emotional, mental aspects of their 
inflammatory arthritis, whereas the pain scale specifically focuses on one phenomenon. 
When looking at rheumatoid arthritis, a prototypical example of inflammatory arthritis, 
the Patient Global Assessment has been widely used not only in clinical practice but also 
in clinical trials and is now a familiar and established outcome measure for this 
population (78). As with the pain scale, its utility in this patient population has yet to be 
determined, but is likely to provide relevant information based on its prior uses in other 
conditions of inflammatory arthritis as well as other rheumatic conditions more broadly.  
 
Objectives:  
The data that is presently published regarding ICI-induced inflammatory arthritis 
has thus far contributed important information for the understanding of this immune 
related adverse event. However, further exploration with these patients is needed. The 
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overall aim of this investigation is to report the experience of one academic center in 
evaluating these patients in terms of both their clinical presentation as well as exploring 
the utility of a patient reported outcomes in the setting of their clinical care. Given the 
relatively scattered information that is currently available in describing this population, 
another part of our aim is to evaluate whether the types of arthritis seen following 
treatment with immune checkpoint inhibitors can lead to a classification system for 
different presentations. Although the clinical phenotypes are to some extent described in 
the literature, the information surrounding these presentations and whether they follow 
established patterns of inflammatory arthritis is still an emerging area of investigation. 
Providing a clinical picture from a larger cohort of patients with a defined classification 
system can provide improved definition for the field as a whole as well as give a more in 
depth clinical understanding that can facilitate improved outcomes through identification 
of better therapeutic options.  
 
In addition to providing the clinical information that is necessary for the 
description of this patient population, review of patient reported outcomes, including the 
Health Assessment Questionnaire, pain visual analogue scale and the Patient Global 
Assessment will also be utilized to aid our understanding of this patient population. 
Given that the Health Assessment Questionnaire is able to provide important information 
that is predictive of outcomes in similar disease states such as rheumatoid arthritis, it is 
reasonable to explore whether similar information can also be obtained from a clinically 
similar cohort, namely those that have experienced inflammatory arthritis as a result of 
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their exposure to oncolytic immunotherapy. As no data is currently available for patient 
reported outcomes with a specific focus on ICI-induced inflammatory arthritis, we will 
aim to see whether this questionnaire provides meaningful clinical information about 




In order to study this patient population, a retrospective review of all patients 
referred to the Immuno-Oncology clinic at the University of Michigan was conducted 
spanning a timeframe of 2016 to 2019. These timeframes correlated with the 
establishment of a collaborative clinic set up between the University of Michigan 
Division of Rheumatology and Division of Medical Oncology to help address the 
increasing number of patients experiencing immune related adverse events requiring 
consultation from a rheumatologist. The University of Michigan Institutional Review 
Board (IRBMED) approved this study as a retrospective review to obtain clinical 
information about patients, including disease characteristics, demographics, clinical 
outcomes, as well as patient reported outcomes. Patients who were over the age of 18 and 
had exposure to an immune checkpoint inhibitor leading to an immune mediated adverse 
event of arthritis that required referral to a rheumatologist were reviewed. Subjects that 
met these qualifications and had a documented Health Assessment Questionnaire, pain 




In total, 30 patients were ultimately found to meet these criteria. Demographic 
information, including age, race, and sex was obtained. Following this, information 
related to their overall clinical picture was collected, including the type of cancer 
diagnosis received, the type or types of immune checkpoint inhibitor that were 
administered, and how the immune related adverse event of inflammatory arthritis 
manifested clinically. Additionally, other immune related adverse events were extracted 
from patient charts and were described as in terms of how many patients experienced a 
given event based on the type of therapy they received, such as monotherapy for either 
CTLA-4 or PD-1/PD-L1 or combination therapy. Information was collected in this same 
fashion with regard to discontinuation of immune checkpoint inhibition therapy that was 
directly related to development of inflammatory arthritis. Inflammatory arthritis was 
defined as a subset of joints with clinically apparent inflammation noted by synovitis, 
reduced range of motion, and swelling of the joint. Patients that were referred and had no 
clinical signs of arthritis at the time of their exam were also considered to have an 
inflammatory arthritis if they had current or prior pain in a given joint or joints, had any 
radiographic evidence of erosions, and had no other medical history that could explain 
these findings, which are typical of inflammatory arthropathies. Subjects with a 
classification of polyarthritis were those patients that had an arthritis that most resembled 
rheumatoid arthritis in that their affected joints were primarily present in the small joints 
of the hands and feet, in particular the MCPs, PIPS, wrists and MTPs). Subjects with pain 
primarily in their hips and shoulders and that had elevated inflammatory markers, in 
particular an elevated sedimentation rate, were considered to have a polymyalgia 
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rheumatica-type presentation of their arthritis. Other patients that had evidence of back 
pain and/or inflammation indicative of spondyloarthropathies were characterized as such, 
and lastly, others that had reported arthralgias and had pre-existing degenerative joint 
disease were characterized as having an exacerbation of osteoarthritis. Given the varied 
presentations of osteoarthritis, we included all the patients who had prior documented 
joint space narrowing, osteophyte formation and/or sub-chondral cysts. Additionally, 
patients who did not meet criteria for the above inflammatory conditions but had these 
findings were classified as osteoarthritis patients. 
 
Patient Reported Outcome Measures 
The Health Assessment Questionnaire was then obtained from the patient medical 
record. As previously described, this questionnaire contains eight different domains that 
relate to activities of daily living. Each domain was scored on a scale of 0 to 3 with 
respect to performing a certain task. A score of 0 represents no difficulty performing the 
task, 1 represents some difficulty in performing the task, 2 representing much difficulty 
in completing the task, and 3 translating to the patient being unable to perform the task. 
The eight domains are then added up and divided by eight for a total score of 0 to 3. 
These scores were then analyzed to assess the differences between different inflammatory 
arthritis subtypes. Specifically, the overall mean for all of our patients was first calculated 
to understand the average score across all arthritis types. Next, we divided the data by 
arthritis subtype and compared the average overall scores for each group to examine any 
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differences between the groups. The scores for each individual domain were also divided 
in this way and analyzed.  
 
The two visual analogue scales were then reviewed and measured. The visual 
analogue scales consist of a 100 mm line where patients are asked to mark their answer to 
the prompt question on a scale from 0 mm to 100 mm, 0 mm representing no pain in the 
case of the pain scale and excellent health on the Patient Global Assessment and 100 mm 
representing severe pain on the pain scale and very poor health on the Patient Global 
Assessment. These values were then averaged to get an overall mean for each of the 
questionnaires. The mean for each of the different arthritis phenotypes was also 
calculated to investigate whether these different presentations of disease were relevant to 
the overall. The values were also then compared to the overall Health Assessment 
Questionnaire values for each patient, with a Pearson correlation being used to determine 
whether any correlation existed between the answers to the pain scale as well as any 







 There were 30 patients that were found to have been treated for immune 
checkpoint inhibitor induced inflammatory arthritis in the Rheumatology clinic that had 
completed Health Assessment Questionnaires and were therefore included in this study. 
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Of these patients, 22 were male and 8 were female. All patients identified their race as 
Caucasian and ethnicity as non-Hispanic or Latino. The age range for our cohort was 53 
years to 95 years with an average age of 69 years. In terms of the malignancy and 
treatment parameters, our cohort contained 24 patients with a diagnosis of stage IV 
metastatic melanoma (24/30, 80%), 1 with a diagnosis of metastatic Merkel cell 
carcinoma (1/30, 3%), 1 with Hodgkin’s lymphoma (1/30, 3%), 1 with a diagnosis of 
metastatic basal cell carcinoma (1/30, 3%), 1 with metastatic squamous cell carcinoma, 
and 2 with metastatic urothelial carcinoma (2/30, 7%). Of the patients with metastatic 
melanoma, 9 (38%) were treated with combination therapy (CTLA-4 and PD-1/PD-L1 
agent), 3 (12%) patients were treated with a CTLA-4 monotherapy, and the remaining 12 
(50%) patients were treated with a PD-1/PD-L1 monotherapy. The other malignancy 
types were split in receiving either PD-1/PD-L1 monotherapy or combination therapy. 
Both of the metastatic urothelial cancer patients received therapy with a PD-1 inhibitor as 
did the Hodgkin’s lymphoma and metastatic basal cell carcinoma patients. The metastatic 
squamous cell carcinoma and Merkel cell carcinoma patients received combination 
therapy. Overall, 16 patients, or 53%, received PD-1/PD-L1 monotherapy, 3, or 10%, 
received CTLA-4 monotherapy, and the remaining 11, or 37%, received combination 
therapy with both a PD-1/PD-L1 and CTLA-4 agent.  
 
Next, we examined the inflammatory arthritis phenotypes exhibited by each 
patient. Table 2 describes the distribution of these particular presentations that were 
found within our cohort. There was a nearly even distribution between the four main 
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types of arthritis that were used for classification purposes as part of this study. The 
polyarticular distribution of joint symptoms was the most common finding with 12 out of 
30, or approximately 40% of patients having this finding. The next most common was the 
exacerbation of osteoarthritis, which was a more difficult arthropathy to classify. This 
finding was based on more on clinical judgement with the presence of arthralgias 
alongside the presence of pre-existing osteoarthritis that was worsened following 
treatment with immune checkpoint inhibitors. In this cohort, 11 patients, or 37%, were 
found to meet these criteria. The remaining patients had presentations that were more 
straightforward with either spondyloarthropathy or PMR-like symptoms. More 
specifically, 3 patients (10%) were found to have a spondyloarthropathy while 4 patients 
(23%) were found to have an arthritis phenotype most consistent with PMR.  
 
We also reviewed patient charts to determine whether or not other immune related 
adverse events were experienced in conjunction with the inflammatory arthritis. Of the 30 
patients in our cohort, we found that a large majority, 87% or 26 out of 30, of our patients 
had in fact experienced other adverse events. Table 3 shows these events and indicates 
which specific therapy was the cause of their symptoms. The most common was colitis, 
with 6 (17%) patients experiencing this symptom in addition to their arthritis. Other 
symptoms included epididymitis, mucositis, fatigue, rash/dermatitis, pancreatitis, 
nephritis, peripheral neuropathy, and elevated liver enzymes. Of note is that fact that the 
patients that did receive combination therapy were also the patients that experienced not 
only the most number of immune related adverse events, but also the most severe side 
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effects. In addition to side effects outside of the inflammatory arthritis, it was discovered 
that 4 of our patients required discontinuation of therapy as a direct result of development 
of inflammatory arthritis. Of these patients, 3 were treated with combination therapy 
while 1 was treated with PD-1/PD-L1 therapy.  
 
Patient charts were also screened for the existence of pre-existing inflammatory or 
auto-immune disorders that may have been present prior to the initiation of treatment, as 
the immune checkpoint inhibitors may have exacerbated these pre-existing conditions 
rather than actually caused new symptoms related to treatment initiation. It was found 
that 2 patients had pre-existing autoimmune conditions, both of which happened to be 
inflammatory arthropathies, one being pre-existent rheumatoid arthritis and one case of 
prior psoriatic arthritis, a type of seronegative spondyloarthropathy. In each case, the 
patients experienced a worsening of their disease, requiring more aggressive treatment 
than had previously been administered. There was also one case of a patient with pre-









Table 3: Demographics and Descriptors. The information in this table gives the basic 
descriptors of our cohort including age, sex, type of ICI administered, irAEs aside from 















Average Age and 
Gender 
-Average age: 73 
-Males: 10 
-Females: 6 
-Average Age: 68 
-Males: 3 
-Females: 0 




























































































While not an autoimmune disease, the vast majority of the patients had pre-
existing osteoarthritis, with 25 of out of 30 (83%) patients having this joint abnormality 
seen on radiographs of the hands and feet. Of these 25 patients, approximately half, or 
48%, were found to have osteoarthritis exacerbation. Aside from the inflammatory 
arthritis, gout, a crystalline arthropathy in which uric acid crystal deposition occurs in the 
joint, was noted as a pre-existing arthropathy in 2 of these patients. Neither of these 
patients reported any worsening of their gout as a result of treatment with immune 
checkpoint inhibitors. 
 
In terms of the Health Assessment Questionnaire responses, analysis of the data 
set is provided in Table 2. Overall, the average score for this patient reported outcome 
was found to be 0.57 ± 0.47 across all types of arthritis and all questionnaire domains. 
Individual scores had ranges from 0 to 1.75, with the overall scoring system allows 
individual scores to be given in increments of 0.125. With this in mind, the average score 
therefore corresponds most directly with the possible individual score of 0.625, indicating 




Therapy due to 
Inflammatory 
Arthritis 
1 patient 0 patients 3 patients 
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highest scoring category was the Hygiene section, with an average score of 0.93 ± 0.85. 
Therefore, on average, most patients had some difficulty in completing the tasks 
associated with hygiene. The section with the lowest average score was the Eating 
section, with an average score of 0.07 ± 0.25, indicating that these patients, on average, 
have no difficulty in activities of daily living that are associated with eating.  
 
In looking at more granular data, the next step was to look at the scores when 
divided between each specific type of arthritis. Table 3 shows the overall data for each 
given subtype of arthritis with the associated scoring for each of the eight domains. While 
the overall average score was 0.57, we did find variation when comparing the averages of 
each specific type of arthritis. The PMR-like phenotype was found to have the highest 
average at 1.03 ± 0.52. Next was the polyarthritis phenotype with an average of 0.58 ± 
0.43 followed by the osteoarthritis exacerbation phenotype with a mean score of 0.52 ± 
0.39. Lastly, the spondyloarthritis phenotype had a mean score of 0.04 ± 0.06. When then 
considering the scores of the arthritis phenotypes that are considered classically 
inflammatory, which includes all phenotypes except osteoarthritis exacerbation, the 
average score is 0.59 ± 0.51 with the score of the exacerbation phenotype being 0.52 ± 
0.39 as previously mentioned. When examining the differences between these two 
groups, there was not found to be a significant difference. The two largest groups, 





Table 4: Health Assessment Questionnaire Data by Arthritis Subtype. This data 
provides the domain by domain scoring for subtype of inflammatory arthritis.  
 
 
We next looked at patients based on their overall questionnaire score. Given that a 









































0.82 1.5 0 0.82 
Overall 
HAQ Score:  
0.58 1.03 0.04 0.52 
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question, we divided our group into those that had a score of 1 or greater and assessed 
each domain. It was found that the overall score for patients when divided in this manner 
was 1.25 ± 0.24 and the domain with the highest overall average was the Activities 
Domain with a score of 2.29 ± 0.45 followed by the Walking domain with a score of 2 ± 
0.53, indicating great difficulty in completing these tasks. When dividing these categories 
further, patients were stratified into those that had a score over 1.2, those that had an 
overall score of 0.8 to 1.2 inclusive, and those that had an overall score of less than 0.8 to 
evaluate whether or not there was any connection between the type of arthritis and the 
severity of the score of the Health Assessment Questionnaire. In total, there were 4 
patients with an overall score of greater than 1.2. Of these, 1 patient had polyarthritis, 2 
patients had PMR-like arthritis and 1 patient had osteoarthritis exacerbation. When 
looking at the next group with overall scores between 0.8 and 1.2, there were a total of 8 
patients, 4 patients with polyarthritis, 3 patients with osteoarthritis exacerbation and 1 
patient with PMR-like arthritis. Looking further at the presentation of these patients, the 
breakdown of their domains indicates that patients with an overall score greater than 1.2 
had the highest average domain scores in the Walking domain and the Activities domain, 
each with a score of 2.25. For those with an average score of between 0.8 and 1.2, the 
highest average domain score fell in the Activities domain. 
 
Review of the pain visual analogue scale showed an overall average among all 
patients of 41.8 ± 31.4 mm with 0 mm representing no pain and 100 mm representing 
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very severe pain. After separating out patients based on their arthritis subtype, the 
exacerbation category had an average pain score of 36.5 ± 32.5 mm, the polyarthritis 
group with a mean of 43.3 ± 32.5 mm, the PMR-like arthritis group with an average of 30 
mm, and the spondyloarthritis group with a mean of 71.3 ± 23.4 mm. Looking at Pearson 
correlations for the overall pain scale mean and the overall Health Assessment 
Questionnaire mean score, we found the correlation coefficient to be 0.231 with a p-value 
of 0.219. The next step was assessing the overall mean score of the osteoarthritis 
exacerbation group pain scale measurements in comparison to the other groups 
combined. The mean for the combined group was 44.9 ± 30.3 mm against the previously 
reported 36.5 ± 32.5 mm for exacerbation patients. The Pearson correlation for the 
combined group pain measurements when compared to the Health Assessment 
Questionnaire scores was found to be 0.139 with a p-value of 0.464, while the same 
comparison but for the exacerbation group found a coefficient of 0.412 and a p-value of 
0.024. 
 
Lastly, the Patient Global Assessment scores were considered. The mean for the 
entire cohort was found to be 25.6 ± 26.7 mm, with 0 mm indicating no disease present 
and 100 mm indicating very severe disease was present. The subtype analysis was then 
performed as with the pain scale. The osteoarthritis group had an average of 20.5 ± 24.4 
mm followed by 30.4 ± 31.6 mm for the polyarthritis group, 24.8 ± 15.3 mm for the PMR 
group and 26.2 ± 21.9 mm for the spondyloarthritis group. Pearson correlations for the 
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overall Health Assessment Questionnaire scores and the overall Patient Global 
Assessment were 0.368 with a p-value of 0.046. The combined groups were then 
reviewed against the exacerbation cohort, with the mean being 28.6 ± 27.6 mm for the 
combined group and 20.5 ± 24.4 mm for the exacerbation group. Pearson correlation 
demonstrated a coefficient of 0.191 for the combined group with a p-value of 0.312, 





 In terms of the inflammatory arthritis phenotypes that were reviewed as part of 
this retrospective analysis, our cohort was found to be consistent with previously reported 
literature (25). Findings showed arthritis presentations that were similar to rheumatoid 
arthritis, polymyalgia rheumatica and seronegative spondyloarthropathies. The 
polyarthritis and osteoarthritis exacerbation phenotypes were most prevalent with the 
seronegative spondyloarthropathies and PMR-like arthritis presenting less frequently. 
Surprisingly, exacerbation of pre-existing osteoarthritis was much more prevalent in this 
cohort than was initially anticipated. Though this has not been previously described in the 
literature as a clinical finding, evidence suggests that this type of arthritis should be 
classified as an inflammatory arthropathy that can be affected by use of immune 
checkpoint inhibitors. In particular, the presence of osteoarthritis in the vast majority of 
this cohort suggests that the inflammatory profile that results from use of immune 
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checkpoint inhibitors could very well lead to exacerbation of osteoarthritis in a large 
percentage of patients for which this is a pre-existing condition. Moreover, based on the 
significant variance in the rate of arthralgias that have been previously reported in 
addition to the variance in inflammation that is seen as part of the osteoarthritic disease 
progression model, it raises the question of whether or not the arthralgias are more than 
pain in the joint, but rather an inflammatory process occurring without significant 
symptoms to warrant clinical work-up. Indeed, even if patients were routinely assessed 
for the presence of osteoarthritis, the variable level of inflammation involved may mean 
inflammation is not detected, and even if it were, may not be of any clinical value, given 
the lack of effective treatment options for those with osteoarthritis.  
 
 
However, exploration into this is warranted. The current treatment guidelines for 
osteoarthritis are significantly different from those of other inflammatory arthropathies 
and represent a difference in the approach. While inflammatory arthritis guidelines call 
for moderate amounts of immunosuppression to reduce the inflammatory burden in 
affected joints, the osteoarthritis treatment guidelines aim to treat pain associated the 
condition by recommending exercise, weight loss, over the counter non-steroidal anti-
inflammatory drugs and pain modulating agents such as duloxetine and tramadol.  
Indeed, the osteoarthritis guidelines explicitly recommend against use of 
immunosuppressive and immunomodulating therapies. The toxicities associated with the 
immunosuppressive agents used with the traditional inflammatory arthritis phenotypes 
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and significant effects these have in terms of increased potential for malignancies and 
infection in comparison to the osteoarthritis guidelines demonstrate a completely 
different approach for treatment of these entities. While there are differences in the 
pathophysiology of osteoarthritis in comparison to an inflammatory arthritis such as 
rheumatoid arthritis that do warrant different treatment recommendations, the significant 
differences associated with the treatment guidelines reflect a philosophical difference 
between the current approach to both osteoarthritis and inflammatory arthropathies that 
are worth noting.  
 
 
Review of the results from the Health Assessment Questionnaire were in line with 
expectations in terms of the polyarthritis cohort and the osteoarthritis exacerbation 
cohort. It was expected that the polyarthritis cohort would have a higher score than the 
exacerbation cohort as this is consistent with previous findings in which rheumatoid 
arthritis, a useful proxy for the polyarthritis cohort, has an average score of 1.2 for this 
outcome measure while osteoarthritis itself has an average score of 0.8 (79). While the 
relative scores were in line with expectations, the absolute scores of 0.58 and 0.52 for the 
polyarthritis and exacerbation categories, respectively, were lower than initially expected. 
The overall findings were predicted to be more consistent with the overall averages that 
have been previously published in the literature. However, when considering that these 
patients were found earlier in their disease state as compared to the general populations of 
rheumatoid arthritis and osteoarthritis and were more carefully managed with specific 
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attention paid to the potential inflammatory side effects associated with immune 
checkpoint inhibitors, lower scores translating to less effect on overall functionality and 
disability is compatible with an expected finding. Indeed, considering that the overall 
averages for the rheumatoid arthritis and osteoarthritis contain not only those early in 
their disease but also those with advanced, late-stage disease, this also reinforces the idea 
that our cohort would express less pronounced effects. The breakdown of the 
questionnaire scores also did not reveal any significant data that one type of arthritis 
might be more debilitating that another following treatment. The distribution of scores 
was relatively even for the rheumatoid arthritis and osteoarthritis patients in terms of 
separation of scores based on pre-existing average score of 1.2 and 0.8, respectively.  
 
 
The other two patient reported outcomes interestingly suggested that the 
correlation with the Health Assessment Questionnaire was not significant expect for 
those with osteoarthritis exacerbation when comparing only these patient scores with 
both the pain visual analogue scale and the Patient Global Assessment. This is most 
likely due to the fact that pre-existing disease with these patients has been a significant 
part of their overall health experience. With exacerbation, it is likely that most are more 
attuned to the changes in their pain and overall disease burden as a result. It would be 
worthwhile to explore whether this is the case in a prospective manner by evaluating 
patients before treatment and assessing osteoarthritis disease burden with radiographs as 
well as these patient reported outcomes to see whether or not there are objective changes 
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and if the questionnaires are able to capture these changes, as it would seem is the case 
with our cohort.  
 
Sample Size Considerations 
The results from the other two categories of patients, namely the PMR-like 
arthritis and the seronegative spondyloarthopathy had scores that were significantly 
different from those of the other two populations. The PMR group unexpectedly had the 
highest rating but only 4 patients, 2 of which had ratings of 1.75, the highest of any 
patient in the cohort, and 1.25, a greater than doubling of the overall average. Likewise, 
for spondyloarthritis, our 3 patients had an average score of 0.04, with one patient 
providing a score of 1 in the Grip domain and all other responses being 0. While it is of 
interest to look at these results, they are of limited value given the small sample sizes. 
Even consideration using non-parametric statistics is of limited value based on the lack of 
sufficient data to draw any significant conclusions. Therefore, while it is possible to 
assess the overall mean and distribution of scores, the results do not speak to any broader 
trend or explanation other than what our data says here about either three or four patients. 
Based on the data we do have about our patients, generally speaking, the effect of any 
type of spondyloarthritis on quality of life and functionality appears to be quite low, as 
only one patients noted some difficulty with one type of functional task. The PMR 
category appears to have much more impact on functionality and quality of life based on 
the responses for these subjects. A not insignificant part of these results is related to the 
small sample size and the retrospective nature of our review. A larger sample size would 
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most certainly lead to a regression to the mean, but it is unclear whether the average for 
each subtype would increase or decrease to cause significant change in the mean itself. 
As was eluded to, the sample size of this cohort and the retrospective nature of the review 
and significant limitations not only for the PMR arthritis and spondyloarthritis, but also 
for the polyarthritis and the osteoarthritis exacerbation, though to a lesser degree for the 
latter categories. The small sample size for the PMR and spondyloarthritis group is 
keeping with previous reports indicating these subtypes of arthritis to be rarer 
musculoskeletal manifestations immune checkpoint inhibitor induced inflammatory 
arthritis. Better understanding of these types of arthritis in this setting would likely 
require a multi-center registry to be able to gather the numbers needed to study these 
more in detail.  
 
Role of Pro-Inflammatory Markers in Inflammatory Arthritis: Future Directions 
In assessing these patients on a more basic level, all the types of arthritis have 
some level of an inflammatory component to their disease. Although the specifics of each 
type of arthritis and how inflammation is mediated in each is still a topic of research, we 
do know that chemokines and cytokines play important pathologic roles in disease onset 
and progression. For example, in psoriatic arthritis, a type of seronegative 
spondyloarthropathy, the past decade of research has indicated the important role played 
by the IL-17/IL-23 axis in both initiating this disease and its propagation. Indeed, there 
are now several treatments aimed at disrupting this very axis that have seen success in 
treating this population. Similarly, as was previously indicated, inflammation also plays 
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an interesting role in onset and progression of osteoarthritis. Specifically, for 
osteoarthritis, it has been suggested that IL-1 beta, TNF alpha and IL-6 are critical 
cytokines in the pathophysiology of the disease, given that they have been found in high 
quantities around the tissue surrounding affected joints in patients with osteoarthritis, 
including the synovial membrane, synovial tissue, cartilage and subchondral bone layer 
(80). Moreover, the elevated cytokine levels have shown positive correlation with the 
radiographic damage such that the higher the levels of cytokines, the more severe the 
damage (80-82), indicating a direct relationship in progression. Rheumatoid arthritis, too, 
has demonstrated elevated cytokine levels as well, including TNF alpha, IL-1 and IL-6.  
 
In providing the overwhelming evidence for the role of cytokines in the picture all 
of the arthritis phenotypes discussed, it becomes clear that more information is needed on 
how the immune checkpoint blockade functions to create an inflammatory state that 
allows for development of such symptoms. As an obvious starting point, biomarker 
studies are needed to tease out the presence and absence of certain chemokines and 
cytokines, based on the knowledge of their role in inflammatory arthropathies in general. 
Further elucidation of this information may then play a role in determining what other 
targets may be viable targets for exploration, such as Th17 cells involved in production of 
these pro-inflammatory mediators or other cellular or biochemical factors. Moreover, this 
information can also provide significant insight into the mechanisms by which immune 
checkpoint inhibition works to activate the immune system overall. While it is known 
that the blockage of an inhibitory signal by the administered drugs leads to activation of 
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T-cells in one fashion or another, more information is then needed about not only the 
downstream effects, but also any other potential mechanisms that may be involved in 
activating the immune system as a direct result of such a blockade. Obtaining this 
information will not only allow a better understanding of the overall mechanism by 
which the immune related adverse events occur in the joints, and more broadly in the 
other tissues affected by these complications. Furthermore, understanding the overall 
mechanism by which these adverse reactions occur also has the potential to lead to novel 
therapeutic options for treatment of these events.  
 
Limitations and Future Considerations  
Based on the information that is currently available, it is clear that one of the 
primary limitations of our understanding of not only the inflammatory arthritis immune 
related adverse reactions, but of immune related adverse events in general is the 
retrospective nature of our data collection. Indeed, in considering the role that biomarkers 
play in the overall process of these events, it is of limited value to measure these 
indicators without a baseline measure with which to compare. This is true of not only this 
type of serum testing, but also of other data, whether it be clinical or otherwise. Given 
that the retrospective nature of this review also encountered these issues, it can be said 
that having baseline knowledge of a patient’s inflammatory markers, including 
sedimentation rate and C-reactive protein as well as clinical data about the patient’s 
musculoskeletal health prior to the initiation of immune checkpoint inhibitor therapy 
would have provided significantly more information that could then be compared to any 
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information obtained following the administration of immune checkpoint inhibitors. 
More to the point, a controlled prospective trial would be the best pathway to obtain this 
type of information. It would allow for control of what data is obtained at what 
timepoints and could then provide a standardized study plan with which results could be 
analyzed. Although this would be the most ideal option, it would be a more difficult plan 
to carry out, as there is no current mechanism to determine which patients might 
experience immune related adverse events as a result of their treatment or which event 
would be experienced, such as hypophysitis versus pneumonitis versus inflammatory 
arthritis. Such an effort would require a large, multi-center trial, a requirement that makes 
any near-term possibilities of achieving this goal unlikely, especially without a more 
specific aim aside from a desire to understand underlying mechanisms more thoroughly. 
 
Despite this, the use of immune checkpoint inhibitors continues to grow as more 
and more indications receive approval for their use. As more and more patients are 
exposed, more and more patients will experience these events, ultimately requiring 
treatment of these events for a greater number of patients. With this anticipated growth in 
use of these therapies will come a growing need for more established treatment 
paradigms and a better understanding of underlying pathophysiology will be essential to 




APPENDIX 1: Health Assessment Questionnaire 
 













DRESSING     
1. Dress yourself? (including tying 
shoelaces and doing buttons) 
0 1 2 3 
2. Shampoo your hair? 0 1 2 3 
ARISING     
3. Stand up from an armless straight chair? 0 1 2 3 
4. Get in and out of bed? 0 1 2 3 
EATING     
5. Cut your meat? 0 1 2 3 
6. Lift a full glass to your mouth? 0 1 2 3 
7. Open a new milk carton? 0 1 2 3 
WALKING     
8. Walk outdoors on flat ground? 0 1 2 3 
9. Climb up five stairs? 0 1 2 3 
Please check any AIDS OR DEVICES that you usually use for any of the above 
activities: 
 
 Devices used for dressing (button hook, zipper pull, etc.)   Walker 
 Special or built-up chair                                                         Crutches 
 Built-up or special utensils                                                    Wheelchair 
 Cane                                                                                           None 
 
Please check any categories for which you usually NEED HELP FROM 
ANOTHER PERSON: 
 
 Dressing and grooming           Eating               None of these 
 



































HYGIENE     
10. Wash and dry your body? 0 1 2 3 
11. Take a tub bath? 0 1 2 3 
12. Get on and off the toilet? 0 1 2 3 
REACH 
    
13. Reach and get down a 5 pound 
object from above your head? (such as 
a bag of sugar) 
0 1 2 3 
14. Bend down to pick up clothing from the 
floor? 
0 1 2 3 
GRIP     
15. Open car doors? 0 1 2 3 
16. Open previously opened jars? 0 1 2 3 
17. Turn faucets on and off? 0 1 2 3 
ACTIVITIES     
18. Run errands and shop? 0 1 2 3 
19. Get in and out of a car? 0 1 2 3 













0 1 2 3 
Please check any AIDS or DEVICES that you usually use for any of the above activities: 
 Raised toilet seat 
 Bathtub seat 
 Jar opener (for jars previously opened) 
 None 
 Long-handled appliances in bathroom 
 Long-handled appliances for reach 
 Bathtub bar 




Gripping and opening things 
Errands and chores  None of these 
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APPENDIX 2: Pain Visual Analogue Scale 
How much pain have you had because of your illness in the past week?  
 
 
NO PAIN         VERY SEVERE PAIN 
 


































APPENDIX 3: Patient Global Assessment 
 
Overall, how severe would you rate your disease today? 
 
 
NO DISEASE       VERY SEVERE DISEASE 
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